Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Charles Bodine (NPI 1740669928)

Field	Value
Entity Type	Individual
Organization	Charles Bodine
Address	3320 Old Jefferson Rd Bldg 700
City	Athens
State	GA
ZIP	30607
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 21, 2015

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

Top-line concentration: this provider reports Total Medicare revenue of $2.3M and the precomputed top 3 Medicare codes by revenue account for 86.5% of this provider's total Medicare revenue, driven primarily by A9607 ($1.5M, 66.3%), J9271 ($360.8K, 15.9%), and 99214 ($98.7K, 4.3%). This indicates a highly concentrated Medicare revenue base where a very small number of services dominate receipts.

Business/service-line implications: the revenue mix is consistent with a specialty oncology practice that delivers high-cost radiopharmaceutical therapy and infusion-based systemic therapy — A9607 is a therapeutic lutetium radiopharmaceutical and J9271 is pembrolizumab, an immunotherapy infusion — while 99214 indicates substantial office E/M activity. Supporting codes such as 96413 (chemotherapy administration), 96367 (additional infusion), 36415 (venipuncture), and lab panels (85025, 80053, 88185) further suggest an integrated infusion and outpatient oncology workflow rather than a solely consultative practice.

Competitive standing on radiopharmaceutical therapy: A9607 accounts for $1.5M (66.3% of Medicare revenue) but ranks only #27 of 44 providers nationally (40th percentile; typical, unremarkable volume for this code), signaling that while A9607 dominates this provider’s revenue locally, the provider is a modest participant on the national stage for this specific therapy. This pattern may reflect a local concentration of high-cost cases or access to a specialized therapy that is not concentrated among the largest national centers.

Competitive standing on immunotherapy: J9271 contributes $360.8K (15.9% of Medicare revenue) yet ranks #1323 of 1841 providers nationally (28th percentile; typical, unremarkable volume for this code), indicating routine use of pembrolizumab but a below-median national footprint in terms of claim volume for this drug. The code’s contribution to revenue is substantial for this provider despite its modest national rank.

Statistical outlier in E/M billing: 99214 accounts for $98.7K (4.3% of Medicare revenue) and ranks #8785 of 479517 providers nationally (98th percentile; extreme outlier, far above typical national volume for this code). This extreme outlier status for a high-level established office visit suggests an unusually large volume of moderate-complexity outpatient evaluation and management encounters relative to peers, which could reflect clinic throughput, chronic-care follow-up patterns, or documentation/billing intensity concentrated in this practice.

Single-payer concentration and contracting risk: Medicaid revenue is none (no Medicaid billing on file), so this provider operates effectively as a single-payer (Medicare) billing entity at the dataset level. Reliance on Medicare ($2.3M) with no Medicaid activity concentrates payer risk and may affect negotiating leverage and vulnerability to Medicare policy changes affecting high-cost oncology drugs and radiopharmaceuticals.

Tenure and market presence: the NPI was enumerated 2015-05-21 (~11 years ago), indicating an established provider who has had time to develop specialty service lines and to adopt high-cost therapies such as radioligand treatment and immunotherapy. This tenure supports the plausibility of the concentrated revenue mix and the presence of integrated infusion/diagnostic services documented in the claims.

Ancillary and supportive revenue lines are present but relatively small: chemotherapy administration (96413, $24.1K), infusion add-ons (96417, $5.9K), growth factors and supportive injectables (J1449 $53.9K, J0885 $11.7K, J0897 $46.4K), iron therapy (J1437 $30K), and routine labs/CMP/CBC (85025 $8.4K, 80053 $5.5K) together indicate the practice provides a range of supportive oncology services. However, these buckets are minor compared with the dominant revenue contribution from A9607 and J9271, reinforcing that high-cost therapeutic agents drive the economics of this provider’s Medicare billing profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

68 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
A9607	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	6,090	$250	$1.5M
J9271	Injection, pembrolizumab, 1 mg	8,800	$40	$360.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,110	$90	$98.7K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	2,240	$20	$53.9K
J0897	Injection, denosumab, 1 mg	2,580	$20	$46.4K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	100	$330	$33.7K
J1437	Injection, ferric derisomaltose, 10 mg	2,000	$20	$30K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	270	$90	$24.1K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	90	$150	$13.5K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	2,330	$10	$11.7K

Showing 1–10 of 68

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 68 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Charles Bodine — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

68 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
A9607	2	10	6,090	$250	$1.6M
J9271	36	40	15,200	$40	$767.3K
J0897	140	290	2,460	$20	$90.2K
J1449	4	10	2,640	$30	$74.9K
J1437	25	30	2,850	$20	$56.4K
J0885	16	30	3,970	$10	$26.6K
J1454	9	20	80	$330	$25.9K
96413	49	160	170	$90	$20.3K
J3490	16	50	50	$320	$19.8K
88185	7	10	530	$20	$18.5K

Showing 1–10 of 68

Related Providers

Other providers that share a Tax Identification Number (TIN) with Charles Bodine, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Petros Nikolinakos	GA	Hematology & Oncology Physician	$4.6M	$0
University Cancer & Blood Center LLC	GA	Hematology & Oncology Physician	$0	$3.2M
Gustavo Westin	FL	Medical Oncology Physician	$2M	$0
James Splichal	GA	Hematology & Oncology Physician	$1.9M	$0
Kuang Chang	GA	Hematology & Oncology Physician	$1.8M	$0
Jeffrey Thomas	GA	Hematology & Oncology Physician	$1.7M	$0
Cynthia Shepherd	GA	Hematology & Oncology Physician	$1.6M	$0
Barry Charnick	FL	Nuclear Radiology Physician	$1.3M	$0
Frederick Flynt	GA	Hematology & Oncology Physician	$1M	$0
Gordon Schoenfeld	GA	Radiation Oncology Physician	$834K	$0

Nearby Providers

Other providers in the same ZIP code as Charles Bodine, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mohan Iyer	GA	Retina Specialist (Ophthalmology) Physician	$1.6M	$0
Victor Copeland	GA	Retina Specialist (Ophthalmology) Physician	$1.5M	$0
Athens Eye Surgery Center,llc	GA	Ambulatory Surgical Clinic/Center	$1.2M	$0
Athens Radiology Associates PC	GA	Diagnostic Radiology Physician	$0	$863K
Tzu-chuan Huang	GA	Hematology & Oncology Physician	$469.2K	$0
Jeffrey Williams	GA	Gastroenterology Physician	$385.8K	$0
Athens Gastroenterology Endoscopy Center Inc	GA	Endoscopy Clinic/Center	$375.9K	$0
Walter Sams	GA	Ophthalmology Physician	$358.3K	$0
Emory Patterson	GA	Ophthalmology Physician	$326.1K	$0
Addie Hill	GA	Hematology & Oncology Physician	$298.2K	$0

Charles Bodine — Billing Profile & Reimbursement Data

Sign up for Charles Bodine — Billing Profile & Reimbursement Data policy alerts

Charles Bodine — Billing Profile & Reimbursement Data

Sign up for Charles Bodine — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References